GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT02647281
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms
Not Applicable
Completed
- Conditions
- Xerostomia
- Interventions
- Other: Biotene mouthwashOther: Mineral Water
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT02641912
- Locations
- πΊπΈ
GSK Investigational Site, Boston, Massachusetts, United States
Safety of 4CMenB Exposure During Pregnancy
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: 4CMenB
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2
- Registration Number
- NCT02640677
- Locations
- πΊπΈ
GSK Investigational Site, Wilmington, North Carolina, United States
Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine
Phase 1
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Investigational MenC-CRM adjuavnted with 50 ug of LHD153RBiological: Investigational MenC-CRM adjuavnted with 100 ug of LHD153RBiological: Investigational MenC-CRM adjuavnted with 25 ug of LHD153RBiological: Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153RBiological: Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT02639351
- Locations
- π©πͺ
GSK Investigational Site, Berlin, Germany
Skin Irritation Study of GSK2894512 Cream
Phase 1
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: GSK2894512 CreamDrug: Vehicle CreamDrug: Empty Patch
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT02637206
- Locations
- π―π΅
GSK Investigational Site, Fukuoka, Japan
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
Phase 2
Completed
- Conditions
- Sjogren's Syndrome
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 86
- Registration Number
- NCT02631538
- Locations
- π¬π§
GSK Investigational Site, Newcastle-upon-Tyne, United Kingdom
Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5
- Registration Number
- NCT02630251
- Locations
- πΊπΈ
GSK Investigational Site, Nashville, Tennessee, United States
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: SenseWear Armband GeckoDevice: SenseWear Armband MFDevice: Actigraph GT9x wristband and waistbandDevice: Garmin Vivofit 2 wristbandDevice: SOMNOwatch plus EEG 6 sleep monitorOther: Strength exercisesOther: Field-based exercise testsOther: Laboratory-based exercise tests
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT02619357
- Locations
- π¬π§
GSK Investigational Site, Cambridge, United Kingdom
Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris
Phase 3
Terminated
- Conditions
- Pemphigus
- Interventions
- Drug: Acetaminophen/paracetamolDrug: Antihistamine (cetirizine or equivalent)Drug: Prednisone/Prednisolone
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT02613910
- Locations
- πΊπΈ
GSK Investigational Site, Ann Arbor, Michigan, United States
First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients
Phase 1
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Drug: GSK3008348 Nebuliser solutionDrug: Placebo Nebuliser solution
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT02612051
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath